IMMURON Ltd/S (NASDAQ:IMRN) received a $20.00 price objective from equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, May 29th. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 108.99% from the company’s previous close.
A number of other research analysts have also issued reports on IMRN. Zacks Investment Research upgraded IMMURON Ltd/S from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Tuesday, March 20th. ValuEngine lowered IMMURON Ltd/S from a “buy” rating to a “hold” rating in a report on Monday, April 2nd.
Shares of IMMURON Ltd/S traded up $0.23, reaching $9.57, during trading on Tuesday, according to MarketBeat.com. The stock had a trading volume of 9,800 shares, compared to its average volume of 12,963. IMMURON Ltd/S has a fifty-two week low of $4.47 and a fifty-two week high of $16.70.
Immuron Limited, a biopharmaceutical company, focuses on the research and development of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that produces antibodies to treat various diseases, including infectious diseases, cancers, and chronic inflammatory diseases.
Receive News & Ratings for IMMURON Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMMURON Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.